Cargando…

Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation

Detalles Bibliográficos
Autores principales:	Lázaro-Navarro, Juan, Pimentel-Gutiérrez, Helia Judith, Gauert, Anton, Hagemann, Anja I. H., Eisenschmid, Jassi, Gökbuget, Nicola, Vick, Binje, Jeremias, Irmela, Seyfried, Felix, Meyer, Lüder Hinrich, Debatin, Klaus-Michael, Richer, Kathrin, Bultman, Miriam, Neumann, Martin, Hänzelmann, Sonja, Serve, Hubert, Astrahantseff, Kathy, Rieger, Michael A., Eckert, Cornelia, Baldus, Claudia D., Bastian, Lorenz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714730/ https://www.ncbi.nlm.nih.gov/pubmed/34610112 http://dx.doi.org/10.1182/bloodadvances.2021004513

Ejemplares similares

A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape
por: Kellner, Markus, et al.
Publicado: (2022)

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Manzano-Muñoz, Albert, et al.
Publicado: (2021)

Fast, In Vivo Model for Drug-Response Prediction in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
por: Gauert, Anton, et al.
Publicado: (2020)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Anti-leukemic effects of the V-ATPase inhibitor Archazolid A
por: Zhang, Siwei, et al.
Publicado: (2015)

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
por: Seyfried, Felix, et al.
Publicado: (2019)

P317: ANTI-LEUKEMIA ACTIVITY OF CD70-DIRECTED IMMUNOTHERAPY IN B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
por: Sun, Qian, et al.
Publicado: (2023)

Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics
por: Koczian, Fabian, et al.
Publicado: (2019)

Prime-seq, efficient and powerful bulk RNA sequencing
por: Janjic, Aleksandar, et al.
Publicado: (2022)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
por: Zhao, Tianming, et al.
Publicado: (2023)

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL
por: Seyfried, Felix, et al.
Publicado: (2022)

Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
por: Zeller, Christina, et al.
Publicado: (2022)

Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state
por: Trentin, Luca, et al.
Publicado: (2018)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes
por: Fischer, Melissa A., et al.
Publicado: (2022)

Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia
por: Koschade, Sebastian E., et al.
Publicado: (2022)

Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia
por: Koschade, Sebastian E., et al.
Publicado: (2022)

Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice
por: Ebinger, Sarah, et al.
Publicado: (2020)

Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia
por: Zhou, Fang-jiao, et al.
Publicado: (2021)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
por: Cho, Hyunsoo, et al.
Publicado: (2021)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

Overcoming apoptosis resistance in high risk acute lymphoblastic leukemia by SMAC mimetics in a preclinical ALL xenograft model in vivo
por: Schirmer, Melanie, et al.
Publicado: (2014)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
por: Fiorcari, Stefania, et al.
Publicado: (2022)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
por: Vick, Binje, et al.
Publicado: (2015)

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction
por: Schulze-Bergkamen, Henning, et al.
Publicado: (2006)

An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse
por: Bartsch, Lorenz, et al.
Publicado: (2022)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells
por: Redondo Monte, Enric, et al.
Publicado: (2020)

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019)

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
por: Garz, Anne-Kathrin, et al.
Publicado: (2017)

Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice
por: Höfig, Ines, et al.
Publicado: (2012)

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
por: Habringer, Stefan, et al.
Publicado: (2018)

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML
por: Kempf, Julia M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c43sg0f08eqr5hhb1rdgv8039u